MAM
REGN icon

McLean Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

McLean Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Sell
267
-5
-2% -$3.4K 0.03% 178
2026
Q1 		$210K Buy
+272
New +$208K 0.04% 162
2024
Q4 		– Sell
-263
Closed -$266K – 164
2024
Q3 		$266K Hold
263
– – 0.08% 130
2024
Q2 		$282K Sell
263
-99
-27% -$96K 0.09% 117
2024
Q1 		$342K Buy
362
+1
+0.3% +$951 0.12% 97
2023
Q4 		$330K Sell
361
-3
-0.8% -$2.47K 0.12% 90
2023
Q3 		$304K Hold
364
– – 0.12% 93
2023
Q2 		$262K Sell
364
-1
-0.3% -$771 0.1% 106
2023
Q1 		$300K Sell
365
-4
-1% -$3.02K 0.12% 93
2022
Q4 		$266K Buy
369
+4
+1% +$2.95K 0.09% 104
2022
Q3 		$264K Buy
365
+9
+3% +$5.67K 0.1% 95
2022
Q2 		$212K Sell
356
-3
-0.8% -$1.95K 0.08% 119
2022
Q1 		$251K Buy
359
+9
+3% +$5.69K 0.19% 102
2021
Q4 		$221K Sell
350
-56
-14% -$34.4K 0.09% 123
2021
Q3 		$240K Hold
406
– – 0.09% 115
2021
Q2 		$237K Buy
+406
New +$206K 0.11% 99
2021
Q1 		– Sell
-414
Closed -$200K – 106
2020
Q4 		$200K Buy
+414
New +$223K 0.18% 94

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

McLean Asset Management's REGN Position: Q2 2026 in Review

McLean Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.8% in Q2 2026, selling an estimated $3.4K and leaving 267 shares worth $204K. The position accounts for 0.03% of the portfolio, ranked #178.

McLean Asset Management first reported a position in REGN in Q4 2020 and has held it in 17 quarters since. The position peaked at $342K in Q1 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • McLean Asset Management held 267 shares of Regeneron Pharmaceuticals worth $204K as of Q2 2026.
  • McLean Asset Management sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
  • Regeneron Pharmaceuticals made up 0.03% of McLean Asset Management's portfolio in Q2 2026, its #178 holding.
  • McLean Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • McLean Asset Management's Regeneron Pharmaceuticals position peaked at $342K in Q1 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on McLean Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.